ChemicalBook > Product Catalog >Pharmaceutical intermediates >Heterocyclic compound >N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

CAS No.: 477600-74-1

Chemical Name:: N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine

Synonyms: tofacitinib intermediate;TF-G;Tofacitinib-11;Tofacitinib N-1;Tofatinib Impurity F;Tofatinib Impurity 41;Tofacitinib IMpurity M;Tofacitinib N-Descyanoacetyl;Azilsartan medoxomil impurity343;H-Pyrrolo[2,3-d]pyriMidin-4-aMine

CBNumber:: CB2970945

Molecular Formula:: C13H19N5

Molecular Weight:: 245.32

MOL File:: 477600-74-1.mol

MSDS File:: SDS

Modify Date:: 2024/5/16 14:11:51

Request For Quotation

N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Properties

Melting point	157 - 162°C
Density	1?+-.0.06 g/cm3(Predicted)
storage temp.	2-8°C(protect from light)
solubility	Aqueous Acid (Slightly), Methanol (Slightly), Water (Slightly, Heated)
form	Solid
pka	13.36±0.50(Predicted)
color	White to Off-White
InChI	InChI=1S/C13H19N5/c1-9-3-5-14-7-11(9)18(2)13-10-4-6-15-12(10)16-8-17-13/h4,6,8-9,11,14H,3,5,7H2,1-2H3,(H,15,16,17)/t9-,11+/m1/s1
InChIKey	XRIARWQZLGCQDM-KOLCDFICSA-N
SMILES	C1=NC(N(C)[C@@H]2[C@H](C)CCNC2)=C2C=CNC2=N1

SAFETY

Risk and Safety Statements

Symbol(GHS)	GHS07
Signal word	Warning
Hazard statements	H315-H319
Precautionary statements	P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313

N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Chemical Properties,Uses,Production

Description

N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine is an important pharmaceutical intermediate that is a by-product of the preparation of tofacitinib. Tofacitinib belongs to a class of Janus kinase (JAK) inhibitors used in the treatment of rheumatoid arthritis and psoriatic arthritis.

Uses

N-Methyl-N-((3S,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine, is an intermediate in the synthesis of (3S,4R)-Tofacitinib (T528010), an enantiopure stereoisomer of the drug, Janus kinase 3(Jak3) inhibitor (CP-690,550) that has been found to inhibit selected members of the STE7 and STE20 subfamily of kinases.

N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Preparation Products And Raw materials

Raw materials

1-Piperidinecarboxylic acid, 4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-, 1,1-dimethylethyl ester, (3R,4R)-

Preparation Products

N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine Suppliers

Global( 244)Suppliers

Supplier	Tel	Country	ProdList	Advantage	Inquiry
PSN Medicare Private Limited	+91-9030090313 +91-7702388996	Telangana, India	82	58	Inquiry
Pharmaffiliates Analytics and Synthetics P. Ltd	+91-172-5066494	Haryana, India	6773	58	Inquiry
SynZeal Research Pvt Ltd	+1 226-802-2078	Gujarat, India	6522	58	Inquiry
CLEARSYNTH LABS LTD.	+91-22-45045900	Hyderabad, India	6351	58	Inquiry
Azaricta Research Labs	08066085870Ext 722	Maharashtra, India	4	58	Inquiry
TAIZHOU YUXIN BIOTECHNOLOGY CO,.LTD	+86-576-88902229;+86-0576-88902229 +8613968687450	China	158	58	Inquiry
Hangzhou ICH Biofarm Co., Ltd	+86-0571-28186870; +undefined8613073685410	China	998	58	Inquiry
Capot Chemical Co.,Ltd.	571-85586718 +8613336195806	China	29798	60	Inquiry
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	China	21662	55	Inquiry
career henan chemical co	+86-0371-86658258 +8613203830695	China	29899	58	Inquiry

Supplier	Advantage
PSN Medicare Private Limited	58
Pharmaffiliates Analytics and Synthetics P. Ltd	58
SynZeal Research Pvt Ltd	58
CLEARSYNTH LABS LTD.	58
Azaricta Research Labs	58
TAIZHOU YUXIN BIOTECHNOLOGY CO,.LTD	58
Hangzhou ICH Biofarm Co., Ltd	58
Capot Chemical Co.,Ltd.	60
Henan Tianfu Chemical Co.,Ltd.	55
career henan chemical co	58

477600-74-1(N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine)Related Search:

Tofacitinib N-Methyl-N-((3S,4S)-4-Methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyriMidin-4-aMine 3-Piperidinamine,4-methyl-1-(phenylmethyl)-,(3R,4R)-rel- methyl3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin -4-yl)amino)piperidin-1-yl)-3-oxopropanoate (3R,4S)-1-benzyl-N,4-dimethylpiperidin-3-amine

(3R,4R)-1-Benzyl-N,4-dimethylpiperidin-3-amine Tofacitinib Impurity 6 (3R,4R)-3-[(6-amino-4-pyrimidinyl)methylamino]-4-methyl-β-oxo-1-Piperidinepropanenitrile 3-((3R,4R)-4-Methyl-3-(Methyl(7H-pyrrolo[2,3-d]pyriMidin-4-yl)aMino)piperidin-1-yl)-3-oxopropanaMide 3-((3R,4R)-3-((2-chloro-7H-pyrrolo[2,3-d]pyriMidin-4-yl)(Methyl)aMino)-4-Methylpiperidin-1-yl)-3-oxopropanenitrile

3-PiperidinaMine, 1-acetyl-N,4-diMethyl-N-1H-pyrrolo[2,3-d]pyriMidin-4-yl-, (3R,4R)- (9CI) 4-Chloro-7H-pyrrolo[2,3-d]pyrimidine 2,4-DICHLORO-7H-PYRROLO2,3-DPYRIMIDINE N-((3R,4R)-1-benzyl-4-methylpiperidin-3-yl)-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine 7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-1-(phenylMethyl)-3-piperidinyl]-7-[(4-Met hylphenyl)sulfonyl]-

4-CHLORO-7-TOSYL-7H-PYRROLO[2,3-D]PYRIMIDINE (3R,4R)-1-benzyl-N,4-dimethylpiperidin-3-amine dihydrochloride Tofacitinib Impurity T

chevron_left

1of4

chevron_right

N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine N-Methyl-N-((3R,4R)-4-Methylpiperidin-3-yl)-7HMethylpiperidin-3-yl)-7Hpyrrolo[ 2,3-d]pyriMidin-4-aMine (3R,4R)-N,4-diMethyl-N-{7H-pyrrolo[2,3-d]pyriMidin-4-yl}piperidin-3-aMine 7H-Pyrrolo[2,3-d]pyriMidin-4-aMine, N-Methyl-N-[(3R,4R)-4-Methyl-3-piperidinyl]- N-Methyl-N-((3R,4R)-4-Methyl-piperidin-3-yl)-N-Methyl-7H-pyrrolo[2,3-d]pyriMidin-4-aMine (3R,4R)-Methyl{(4-Methylpiperidin-3-yl)(7H-pyrrolo[2,3-d]pyriMidin-4-yl)}aMine 1H-Pyrrolo[2,3-d]pyriMidin-4-aMine,N-Methyl-N-[(3R,4R)-4-Methyl-3-piperidinyl]- (9CI) H-Pyrrolo[2,3-d]pyriMidin-4-aMine N-Methyl-N-[(3R,4R)-4-Methylpiperidin-3-yl]-7H-pyrrolo[2,3-d] Tofacitinib IMpurity M N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-1H-pyrrolo[2,3-d]pyrimidin-4-amine N-methyl-N-((3S,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine TF-G Tofacitinib-11 Tofacitinib N-Descyanoacetyl Tofacitinib impurity 7/N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amin Tofacitinib N-Descyanoacetyl Impurity N-Methyl-N-[(3R,4R)-4-methyl-3-piperidyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine N-METHYL-N-((3R,4R)-4-METHYLPIPERIDIN-3-YL)-7H-PYRROLO[2,3-D]PYRIMIDIN-4-AMINE (CAS NO.477600-74-1) Tofacitinib Impurity-M(debenzylated) N-Methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-1H-Pyrrolo[2,3-d]pyrimidin-4-amine Azilsartan medoxomil impurity343 N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine bis(2,2,2-trifluoroacetate) N-methyl-N-((3R,4R)-4-methylpiperidin-3-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine 477600-74-1 1H-Pyrrolo[2,3-d]pyrimidin-4-amine,N-methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]- Tofacitinib N-1 tofacitinib intermediate N-Methyl-N-[(3R,4R)-4-methyl-3-piperidinyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine Tofatinib Impurity 41 Tofatinib Impurity F 477600-74-1 477660-74-1